News | July 18, 2022
China Pharma submits plan of compliance to NYSE American
The company was directed to submit a plan of compliance by July 15, 2022
The company was directed to submit a plan of compliance by July 15, 2022
The approval has been accorded by IFCI Limited for manufacturing of the product "7 ACA"
Fermentation-based manufacturing leverages Evonik’s biotechnology platform
The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.
Submission seeks approval for the treatment of COVID-19 in both vaccinated and unvaccinated individuals at high risk
Intended for potential treatment of ER+/HER2- advanced or metastatic breast cancer patients
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
The revamped Ayushman Bharat Health Account (ABHA) mobile application offers added functionalities and a new User Interface (UI)
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
Subscribe To Our Newsletter & Stay Updated
